The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / The New Front Line of STI Diagnosis
Omics Precision medicine Research and Innovations Molecular Pathology

The New Front Line of STI Diagnosis

Point-of-care and at-home tests are expanding access while creating new challenges for reporting and public health surveillance

By Nikolina Babic, Sheldon Campbell, Kate Crawford 11/18/2026 Discussion 5 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: The New Front Line of STI Diagnosis

At a Glance

CategoryDetail
ConditionSexually transmitted infections, including chlamydia, gonorrhea, syphilis, HIV, Mycoplasma genitalium, and Trichomonas vaginalis
Key MechanismsPOC assays provide results near the patient, typically within minutes to an hour. Rapid antibody and antigen-antibody tests for syphilis and HIV commonly use fingerstick whole blood and return results in under 30 minutes; rapid molecular nucleic acid amplification tests detect chlamydia and gonorrhea in approximately 20 minutes.
Target PopulationPeople undergoing STI testing, including adolescents and young adults, men who have sex with men, pregnant people, racial and ethnic minority populations, people with limited access to health care, people experiencing homelessness, migrants, and people with unstable housing or insurance coverage.
Care SettingClinical, public health, community-based, and other care settings where same-visit results are useful, especially when follow-up may be difficult.

Key Highlights

  • Many STIs are asymptomatic, and delayed diagnosis can contribute to complications and continued transmission.
  • Rapid molecular POC assays for chlamydia and gonorrhea can provide results in approximately 20 minutes, with accuracy approaching laboratory-based testing.
  • Same-visit results can support diagnosis and treatment during one encounter and reduce dependence on follow-up visits.
  • POC testing may reduce reliance on syndromic treatment and unnecessary antibiotic exposure.
  • POC testing has limitations, including cost, operational complexity, specimen restrictions, and the need for training and quality oversight.

Guideline-Based Recommendations

Diagnosis

  • Select POC tests according to the organism, assay performance, and approved specimen types.
  • FDA-cleared, CLIA-waived rapid molecular assays are available for chlamydia and gonorrhea; some newer platforms also test for Mycoplasma genitalium and Trichomonas vaginalis.
  • POC tests for herpes simplex virus and human papillomavirus are not yet available.

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        STI testing is relevant across populations; the article identifies adolescents and young adults, men who have sex with men, pregnant people, racial and ethnic minority populations, people with limited access to care, people experiencing homelessness, migrants, and people with unstable housing or insurance coverage as groups at increased risk or facing barriers to care.

        The article provides no drug regimens or dosing. Same-visit diagnosis may allow treatment to begin immediately and reduce reliance on empiric treatment.

        Clinical Best Practices

        • Match the POC assay and specimen to the organism and the test's approved use.
        • Integrate POC testing with staff training, competency assessment, quality control, and laboratory oversight.
        • Consider access barriers and the likelihood of follow-up when selecting a testing approach.
        • Use POC testing as a complement to centralized laboratory services, not as a replacement.

        Related Resources & Content

          This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

          Newsletters

          Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

          Newsletter Signup Image

          About the Author(s)

          Nikolina Babic

          Nikolina Babic is Board-certified clinical chemist and Professor of Pathology and Laboratory Medicine, Medical University of South Carolina.

          More Articles by Nikolina Babic

          Sheldon Campbell

          Sheldon Campbell is Professor of Laboratory Medicine, Yale School of Medicine, and Director of Clinical Laboratories, VA Connecticut Healthcare System.

          More Articles by Sheldon Campbell

          Kate Crawford

          Kate Crawford is Acting Assistant Professor, Department of Laboratory Medicine and Pathology, University of Washington.

          More Articles by Kate Crawford

          Explore More in Pathology

          Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

          False

          Advertisement

          Recommended

          False

          Affiliations:

          Specialties:

          Areas of Expertise:

          Contributions:

          False

          The Pathologist
          Subscribe

          About

          • About Us
          • Work at Conexiant Europe
          • Terms and Conditions
          • Privacy Policy
          • Your Privacy Choices
          • Advertise With Us
          • Contact Us

          Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.